z-logo
Premium
Polymorphism of HLA‐DRB1 gene shows no strong association with ulcerative colitis in Chinese patients
Author(s) -
Lü M.,
Xia B.
Publication year - 2006
Publication title -
international journal of immunogenetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.41
H-Index - 47
eISSN - 1744-313X
pISSN - 1744-3121
DOI - 10.1111/j.1744-313x.2005.00559.x
Subject(s) - ulcerative colitis , hla drb1 , genotype , allele , genotyping , bonferroni correction , statistical significance , medicine , gastroenterology , human leukocyte antigen , polymorphism (computer science) , immunology , biology , genetics , gene , antigen , disease , statistics , mathematics
Summary The genetic factors predisposing to ulcerative colitis (UC) have remained totally unclear to date. This study aimed to investigate the role of HLA‐DRB1 genetic polymorphism in the susceptibility to develop UC in Chinese patients. HLA‐DRB1 genotyping was carried out in 72 unrelated patients with UC and 314 healthy controls by using polymerase chain reaction–sequence‐specific primers (PCR‐SSP). All of the patients and healthy controls are Han people in China. The frequency of DRB1*07 allele was increased in UC patients compared with healthy controls (19.4% vs. 9.2%, P  = 0.0229, OR = 2.372, 95%CI: 1.181–4.766), but the significance disappeared when given Bonferroni correction ( P C  = 0.2977). Furthermore, compared with healthy controls, although HLA‐DRB1*07, DRB1*16/DRB1*09 and DRB1*07/DRB1*12 genotypes were increased in frequency in the patients with extensive colitis, and the patients without extraintestinal manifestations (EIMs) carried an increased frequency of HLA‐DRB1*07 and DRB1*07/DRB1*12 genotypes, these differences did not reach statistical significance after Bonferroni correction. HLA‐DRB1 alleles showed no strong association with UC, and no HLA‐DRB1 alleles or genotypes were strongly associated with clinical subgroups of UC in Chinese patients.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here